



**4<sup>th</sup> POSTGRADUATE**  
**Lymphoma**  
**Conference**

Rome,  
March 15-16  
2018

VOI Donna Camilla Savelli Hotel

**President:**

P.L. Zinzani

**Scientific Committee:**

B.D. Cheson

A. Younes

P.L. Zinzani

# Rome, March 15-16 2018

## Faculty

Christian	<b>Buske</b>	Ulm, Germany
Robert	<b>Chen</b>	Duarte, USA
Bruce D.	<b>Cheson</b>	Washington, USA
Andreas	<b>Engert</b>	Cologne, Germany
Andre	<b>Goy</b>	Hackensack, USA
Georg	<b>Lenz</b>	Munster, Germany
Giampaolo	<b>Merlini</b>	Pavia, Italy
Frank	<b>Morschhauser</b>	Lille, France
Sattva S.	<b>Neelapu</b>	Houston, USA
Grzegorz S.	<b>Nowakowski</b>	Rochester, USA
Owen A.	<b>O'Connor</b>	New York, USA
M. Lia	<b>Palomba</b>	New York, USA
Simon	<b>Rule</b>	Plymouth, United Kingdom
Carole	<b>Soussain</b>	Saint-Cloud, France
Constantine	<b>Tam</b>	Melbourne, Australia
Steven P.	<b>Treon</b>	Boston, USA
Wyndham H.	<b>Wilson</b>	Bethesda, USA
Anas	<b>Younes</b>	New York, USA
Pier Luigi	<b>Zinzani</b>	Bologna, Italy

Thursday, March 15, 2018

8.30 am Welcome and Introduction  
*P.L. Zinzani*

## Session I

### **Hodgkin Lymphoma**

*Chairman: A. Younes*

8.45 am **Problem statement: what are the key issues in treating early stage HL?**  
*A. Engert*

9.00 am General discussion

9.15 am **New scenario for frontline advanced stage HL**  
*A. Younes*

9.30 am General discussion

9.45 am **Managing risk in advanced stage HL**  
*A. Engert*

10.00 am General discussion

10.15 am **Treatment approaches in relapsed/refractory HL:**  
• **Brentuximab vedotin** *A. Younes*  
• **Anti-PD1** *A. Engert*  
• **Anti-PDL1** *R. Chen*  
• **The “combo news”** *A. Younes*

11.15 am **Panel Discussion:**  
**What does the future hold for advanced-stage HL?**  
*R. Chen, A. Engert, A. Younes*

11.45 am *Coffee break*

## Hodgkin Lymphoma

Thursday, March 15, 2018

## Session II

### **Waldenström's Macroglobulinemia**

Chairman: *S.P. Treon*

12.00 pm **Diagnosis, clinical manifestations and conventional treatment**

*G. Merlini*

12.15 pm General discussion

12.30 pm **Ibrutinib**

*S.P. Treon*

12.45 pm **Second generation BTK inhibitors: Acalabrutinib and BGB-3111**

*C. Tam*

1.00 pm **CAR-T therapy**

*M.L. Palomba*

1.15 pm General discussion

1.30 pm *Lunch*

Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia 3

## Session III

### **Follicular Lymphoma**

Chairman: *B.D. Cheson*

2.30 pm **Untangling the complexities of FL: current treatment challenges in frontline**

*B.D. Cheson*

2.45 pm General discussion

3.00 pm **New biological agents (single agent and combo):**

- **PI3K inhibitors** *O.A. O'Connor*
- **BTK inhibitors and BCL-2 inhibitors** *C. Tam*
- **Checkpoint inhibitors** *C. Buske*

4.00 pm General discussion

4.15 pm **Can we foresee a chemo-free treatment for FL?**

*F. Morschhauser*

4.30 pm General discussion

4.45 pm **Perceptual evolution on biosimilar rituximab**

*C. Buske*

5.00 pm General discussion

5.15 pm **With the advent of targeted agents is there a role for transplant in FL?**

*B.D. Cheson*

5.30 pm General discussion

Follicular Lymphoma

Follicular Lymphoma 4

Friday March 16, 2018

## Session IV

### Diffuse Large B-Cell Lymphoma

Chairman: *P.L. Zinzani*

- 8.30 am **Update on pathobiology and biomarkers**  
*G. Lenz*
- 8.45 am General discussion
- 9.00 am **Frontline treatments: what have we learned from the recent trials?**  
*G.S. Nowakowski*
- 9.15 am General discussion
- 9.30 am **Changing treatment landscape in relapsed/refractory patients: novel targets and new strategies**  
*W.H. Wilson*
- 9.45 am General discussion
- 10.00 am **The role of CAR T-cells**  
*S.S. Neelapu*
- 10.15 am General discussion
- 10.30 am **The role of Ibrutinib in relapsed/refractory primary CNS lymphoma**  
*C. Soussain*
- 10.45 am General discussion
- 11.00 am *Coffee break*

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma 5

## Session V

### Mantle Cell Lymphoma

Chairman: *A. Younes*

- 11.15 am **New scenario and concepts in front-line treatment for young patients**  
*A. Goy / A. Younes*
- 11.30 am General discussion
- 11.45 am **The complexities in relapsed/refractory setting:**
- **Lenalidomide** *A. Goy / A. Younes*
  - **Ibrutinib and second generation of BTK inhibitors** *S. Rule*
  - **Combination of ibrutinib and venetoclax** *C. Tam*
- 12.45 pm **Panel discussion**  
*S. Rule, C. Tam, A. Younes*
- 1.15 pm Arrivederci *P.L. Zinzani*

Mantle Cell Lymphoma

Mantle Cell Lymphoma 6

With an unrestricted educational grant of:



## GENERAL INFORMATION

### Meeting Venue

VOI Donna Camilla Savelli Hotel  
Via Garibaldi, 27  
00153 Rome, Italy  
Phone: +39 06 588861  
[www.hoteldonnacamillasavelli.com](http://www.hoteldonnacamillasavelli.com)

### Official Language

English

### Slides

Slides must be in English. Computer videoprojection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible. Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

### Badge

All registered participants and speakers will be given a badge which they must wear to be admitted to the scientific sessions.

### Attendance certificate

A certificate will be given to all participants at the end of the meeting.

### CME

An application for Italian CME credits has been made as follows:

- Provider Studio ER Congressi SRL: ID 828-208928
- No. 12 CME credits for physicians (disciplines: Hematology, Oncology, Radiotherapy)
- Educational objective: "guidelines-protocols-procedures"

### Changes

Parts of the program may be changed without notice.

### Organizing Secretariat

Studio E.R. Congressi  
Via Marconi, 36 - 40122 Bologna  
Phone: +39 051 4210559 - Fax: +39 051 4210174  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)